$0.35
3.74% yesterday
Nasdaq, Dec 24, 10:45 pm CET
ISIN
US41015N1063
Symbol
NVNO

Hancock Jaffe Laboratories, Inc. Stock price

$0.35
+0.01 2.75% 1M
-3.81 91.47% 6M
-2.67 88.25% YTD
-2.47 87.42% 1Y
-4.19 92.19% 3Y
-7.58 95.53% 5Y
-130.65 99.73% 10Y
-130.65 99.73% 20Y
Nasdaq, Closing price Wed, Dec 24 2025
+0.01 3.74%

Key metrics

Basic
Market capitalization
$7.2m
Enterprise Value
$-23.8m
Net debt
positive
Cash
$31.0m
Shares outstanding
20.2m
Valuation (TTM | estimate)
P/E
negative | negative
P/S
- | -
EV/Sales
- | -
EV/FCF
1.4
P/B
0.2
Financial Health
Equity Ratio
93.8%
Return on Equity
-52.2%
ROCE
-78.8%
ROIC
-
Debt/Equity
0.0
Financials (TTM | estimate)
Revenue
$0.0 | $0.0
EBITDA
$-23.7m | -
EBIT
$-23.6m | $-24.2m
Net Income
$-22.0m | $-22.3m
Free Cash Flow
$-17.2m
Growth (TTM | estimate)
Revenue
- | -
EBITDA
-3.3% | -
EBIT
-0.8% | -1.0%
Net Income
-3.4% | -1.2%
Free Cash Flow
-3.0%
Margin (TTM | estimate)
Gross
-
EBITDA
- | -
EBIT
-
Net
- | -
Free Cash Flow
-
More
EPS
$-1.1
FCF per Share
$-0.9
Short interest
11.7%
Employees
37
Rev per Employee
$0.0
Show more

Is Hancock Jaffe Laboratories, Inc. a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 7,079 stocks worldwide.

Hancock Jaffe Laboratories, Inc. Stock Analysis

Unlock Scores for Free

Analyst Opinions

6 Analysts have issued a Hancock Jaffe Laboratories, Inc. forecast:

3x Hold
50%
3x Sell
50%

Analyst Opinions

6 Analysts have issued a Hancock Jaffe Laboratories, Inc. forecast:

Hold
50%
Sell
50%

Financial data from Hancock Jaffe Laboratories, Inc.

Income Statement P&L | Balance Sheet | Cash Flow


Quarter TTM Annually
Sep '25
+/-
%
- -
-
100%
- Direct Costs - -
-
-
- -
-
-
- Selling and Administrative Expenses 12 12
3% 3%
-
- Research and Development Expense 12 12
1% 1%
-
-24 -24
3% 3%
-
- Depreciation and Amortization -0.11 -0.11
124% 124%
-
EBIT (Operating Income) EBIT -24 -24
1% 1%
-
Net Profit -22 -22
3% 3%
-

In millions USD.

Don't miss a Thing! We will send you all news about Hancock Jaffe Laboratories, Inc. directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

Hancock Jaffe Laboratories, Inc. Stock News

Neutral
Accesswire
29 days ago
Moderated webcast with Robert Berman, Chief Executive Officer of enVVeno Medical on Wednesday, December 3rd at 4:00 PM ET IRVINE, CA / ACCESS Newswire / November 26, 2025 / enVVeno Medical Corporation (Nasdaq:NVNO) ("enVVeno Medical" or the "Company"), today announced that Robert Berman, Chief Executive Officer of enVVeno Medical will participate in a Live Virtual Investor CEO Connect segment o...
Neutral
Accesswire
about one month ago
IRVINE, CA / ACCESS Newswire / November 13, 2025 / enVVeno Medical Corporation (NASDAQ:NVNO) ("enVVeno" or the "Company"), a company setting new standards of care for the treatment of deep venous disease, today announced that it has received an unfavorable decision from the U.S. Food & Drug Administration ("FDA") in response to its supervisory appeal of the not-approvable letter it received on ...
Neutral
Accesswire
about 2 months ago
- Cash and investments are sufficient to fund current operations through Q2 2027, not including VenoValve commercialization and the enVVe IDE study - Cash burn of $4.2 million in Q3 remains in line with projected quarterly range - Ongoing engagement with FDA for supervisory appeal of the VenoValve PMA decision with feedback expected by the end of 2025 IRVINE, CA / ACCESS Newswire / October 31, ...
More Hancock Jaffe Laboratories, Inc. News

Company Profile

Hancock Jaffe Laboratories, Inc. is a development stage medical device company, which develops tissue based solutions that are designed to be life sustaining or life enhancing for patients with cardiovascular disease, and peripheral arterial and venous disease. Its products include The Bioprosthetic Heart Valve, The CoreoGraft, and The Venous Valve. The company was founded by Norman Jaffe on December 22, 1999 and is headquartered in Irvine, CA.

Head office United States
CEO Robert Berman
Employees 37
Founded 1999
Website envveno.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today